1. Home
  2. Medical News
  3. Infectious Disease
advertisement

C. auris Genomics Reveal Fluconazole Resistance in Seoul Isolates

Illustrated Candidozyma auris yeast cells representing genomic variation in isolates studied for fluconazole resistance
11/17/2026

Key Takeaways

  • In a Seoul tertiary-care collection dominated by ear-discharge Candidozyma auris isolates, clade II predominated.
  • Fluconazole resistance among patients’ first isolates was not fully explained by recognized coding variants.
  • Serial clade II isolates from the same patient were genomically closer than isolates from different patients.
  • A subclade Ib urine isolate recovered after hospital transfer met tentative resistance criteria for fluconazole, amphotericin B, and caspofungin.
Interpreting resistance and genomic relatedness in Korea’s ear-associated Candidozyma auris (C. auris) presents a clinical laboratory challenge: closely related isolates do not necessarily establish transmission, and a resistant isolate may lack a recognized explanatory variant. A non-ear isolate recovered after interhospital transfer raises a separate question about how C. auris entered the receiving healthcare setting.

Park and colleagues retrospectively assembled 35 archived isolates from 29 patients at a Seoul tertiary-care center between May 2017 and January 2023 for their whole-genome characterization in Microbial Genomics. Most ear specimens came from outpatients; 34 specimens were ear discharge and one was urine. Patient-level susceptibility summaries used only each person’s first isolate. Investigators tested all isolates with Sensititre YeastOne YO10 and Illumina whole-genome sequencing, compared species identification by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and VITEK-2, and assigned genomic clades. They compared single-nucleotide polymorphism (SNP) distances within clades, curated resistance-associated coding variants against two references, and assessed chromosome 6 subtelomeric regions. Tentative C. auris breakpoints from the U.S. Centers for Disease Control and Prevention (CDC) informed fluconazole, amphotericin B, and echinocandin classifications; other drug results were not categorized.

Clade II accounted for 34 of 35 archived isolates, while the urine isolate belonged to subclade Ib. Among patients’ first isolates, 14 of 29 (48.3%) met the CDC tentative fluconazole-resistance criterion. Amphotericin B and caspofungin resistance were uncommon among first isolates, and none met tentative resistance criteria for anidulafungin or micafungin. TAC1B F214S and W198C and ERG11 K143R occurred among resistant first clade II isolates, but recognized coding variants did not account for every resistant clade II isolate; their presence alone did not establish causation.

Among clade II isolates, median SNP distance was 8.5 for same-patient pairs versus 181 for different-patient pairs, an internal measure of relatedness rather than a transmission cutoff. Clade II genomes had a broadly conserved subtelomeric deletion background, with variable chromosome 6 loss and detection of selected glycosylphosphatidylinositol-anchor genes. The distinct urine isolate, recovered on hospital day 28 after transfer, carried ERG11 Y132F, TAC1B A583S, and a CDR1 V704L/E709D-like change. It met CDC tentative resistance breakpoints for fluconazole, amphotericin B, and caspofungin, without an established classification as resistant to every antifungal.

Retrospective sampling at one center, largely from outpatient ear specimens, cannot characterize the overall institutional burden or current inpatient transmission. Short-read sequencing and a mainly coding-focused assessment may miss noncoding, regulatory, or structural contributors to resistance; the candidate variants were not causally established. SNP distances describe relative relatedness within this collection, not universal transmission thresholds. Without linked sampling, the urine isolate’s geographic origin and onward spread remain unresolved. Paradoxical growth can complicate caspofungin susceptibility interpretation, and the tentative three-drug classification does not establish pan-resistance. Clinical consequences of chromosome 6 gene variation were not established.

According to the investigators, the collection shows predominant clade II alongside fluconazole resistance that recognized coding changes do not fully explain. They identified a distinct lineage after healthcare transfer and described transfer as a possible introduction pathway, without establishing where that isolate originated or whether it spread.

Clinician Questions

How did MALDI-TOF MS and VITEK-2 identify the Korean C. auris isolates?

In the Seoul collection, MALDI-TOF MS identified every archived isolate as C. auris, whereas VITEK-2 identified every one as Candida duobushaemulonii.

Why is the origin of the transfer-associated clade Ib C. auris urine isolate uncertain?

A day-1 endotracheal aspirate surveillance culture from the transferred patient was subsequently identified as C. auris but was not archived for genomic comparison. Genomes from the referring hospital and environmental sampling were unavailable. The archived urine isolate was recovered later, and no additional non-otologic hospital isolates were identified over the following year. Those observations do not identify its source or establish onward transmission.

This content is intended for healthcare professionals for educational purposes. The article and its image were developed with AI assistance and reviewed by members of the ReachMD team prior to publication. Please refer to the original source linked for the complete and most up-to-date information.

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free